AbbVie Inc. $ABBV Shares Sold by Generate Investment Management Ltd

Generate Investment Management Ltd reduced its position in AbbVie Inc. (NYSE:ABBV) by 38.5% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 34,188 shares of the company’s stock after selling 21,383 shares during the period. Generate Investment Management Ltd’s holdings in AbbVie were worth $8,943,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the business. MinichMacGregor Wealth Management LLC boosted its position in AbbVie by 72.8% during the third quarter. MinichMacGregor Wealth Management LLC now owns 2,516 shares of the company’s stock valued at $658,000 after purchasing an additional 1,060 shares in the last quarter. First Citizens Bank & Trust Co. raised its holdings in AbbVie by 25.4% in the third quarter. First Citizens Bank & Trust Co. now owns 54,546 shares of the company’s stock worth $14,269,000 after purchasing an additional 11,032 shares in the last quarter. Fearless Solutions LLC dba Best Invest raised its holdings in AbbVie by 0.4% in the third quarter. Fearless Solutions LLC dba Best Invest now owns 12,615 shares of the company’s stock worth $3,300,000 after purchasing an additional 47 shares in the last quarter. ASK Capital Investment Managers LLC bought a new stake in shares of AbbVie in the 3rd quarter valued at about $5,703,000. Finally, XY Planning Network Inc. grew its position in shares of AbbVie by 33.4% in the 3rd quarter. XY Planning Network Inc. now owns 1,846 shares of the company’s stock worth $483,000 after buying an additional 462 shares during the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie Stock Performance

ABBV stock traded up $9.69 during trading on Wednesday, reaching $284.05. The company had a trading volume of 1,608,315 shares, compared to its average volume of 6,389,302. The company has a market cap of $501.85 billion, a price-to-earnings ratio of 80.27, a price-to-earnings-growth ratio of 1.28 and a beta of 0.24. AbbVie Inc. has a twelve month low of $190.75 and a twelve month high of $284.64. The firm has a 50-day simple moving average of $260.41 and a 200-day simple moving average of $237.87.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. During the same quarter in the prior year, the business posted $2.97 EPS. AbbVie’s revenue for the quarter was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Sell-side analysts expect that AbbVie Inc. will post 13.95 earnings per share for the current year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.4%. AbbVie’s payout ratio is 195.48%.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Positive SKYRIZI Crohn’s disease data: New Phase 3 AFFIRM results showed that subcutaneous SKYRIZI generated higher clinical and endoscopic response rates than placebo in adults with moderately to severely active Crohn’s disease. The data strengthen the outlook for AbbVie’s leading immunology franchise and its ability to support long-term growth. AbbVie’s Crohn’s Disease Drug SKYRIZI Shows More Positive Results
• Positive Sentiment: Growth engines remain in focus: Recent SKYRIZI and RINVOQ updates have reinforced expectations that the therapies can offset Humira’s continuing decline. RBC also expects the products, along with Vraylar, to support a potential third-quarter revenue beat. AbbVie Poised for Q3 Top-Line Beat
• Positive Sentiment: Supportive analyst backdrop: Royal Bank of Canada reaffirmed its outperform rating, while Erste Group raised its FY2027 EPS forecast to $16.34 from $16.19 and maintained a Buy rating. These actions add to investor confidence ahead of earnings.
• Neutral Sentiment: Institutional interest is mixed: Recent filings showed substantial buying by several large institutions, although other investors reduced their positions. One AbbVie executive also sold shares, but the transaction does not appear to be a central driver of the session.
• Negative Sentiment: Valuation and execution risks remain: AbbVie trades near its 52-week high, and some valuation analysis suggests the shares may be ahead of estimated fair value. Investors also remain focused on Humira erosion, competition in immunology, and the company’s elevated growth expectations.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ABBV. Morgan Stanley boosted their price objective on shares of AbbVie from $296.00 to $310.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 7th. Erste Group Bank upgraded shares of AbbVie from a “hold” rating to a “buy” rating in a research note on Wednesday, August 5th. Bank of America restated a “buy” rating on shares of AbbVie in a research note on Tuesday, September 8th. Rothschild & Co Redburn lifted their price target on shares of AbbVie from $284.00 to $285.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. Finally, Wall Street Zen downgraded AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 5th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $277.18.

Insider Buying and Selling at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. This represents a 30.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.06% of the stock is owned by company insiders.

AbbVie Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.